

CORRECTION

Open Access



Correction: Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy

Seyed Hossein Kiaie^{1,2*}, Hossein Salehi-Shadkami^{1,3}, Mohammad Javad Sanaei⁴, Marzieh Azizi⁵, Mahdieh Shokrollahi Barough⁶, Mohammad Sadegh Nasr⁷ and Mohammad Sheibani^{8,9*}

Correction: Journal of Nanobiotechnology (2023) 21:339
<https://doi.org/10.1186/s12951-023-02083-y>

The graphic abstract was missing from this article (and should have appeared as below).

The original article can be found online at <https://doi.org/10.1186/s12951-023-02083-y>.

*Correspondence:

Seyed Hossein Kiaie

hosseinkiaie@gmail.com; s.kiaie@renap.ir

Mohammad Sheibani

Mohammad.sheibani89@gmail.com; sheibany.m@iums.ac.ir

¹ Department of Formulation Development, ReNAP Therapeutics, Tehran, Iran

² Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran

³ Department of Medical Science, Tehran University of Medical Sciences, Tehran, Iran

⁴ Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord 8815713471, Iran

⁵ Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran

⁶ Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran 1449614535, Iran

⁷ Department of Computer Science and Engineering Multi-Interprofessional Center for Health Informatics (MICH), The University of Texas at Arlington, Arlington, TX, USA

⁸ Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

⁹ Razi Drug Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.



The original article has been revised.

Author details

¹Department of Formulation Development, ReNAP Therapeutics, Tehran, Iran. ²Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. ³Department of Medical Science, Tehran University of Medical Sciences, Tehran, Iran. ⁴Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord 8815713471, Iran. ⁵Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran. ⁶Department

of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran 1449614535, Iran. ⁷Department of Computer Science and Engineering Multi-Interprofessional Center for Health Informatics (MICHI), The University of Texas at Arlington, Arlington, TX, USA. ⁸Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. ⁹Razi Drug Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Published online: 18 November 2023

Reference

1. Kiaie SH, Salehi-Shadkami H, Sanaei MJ, Azizi M, ShokrollahiBarough M, Nasr MS, Sheibani M. Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy. *J Nanobiotechnology*. 2023;21(1):339.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

